Sanofi Prevails Over Mylan At Fed. Circ. On Jevtana Patent
The Federal Circuit signed off Friday on a Patent Trial and Appeal Board decision allowing Sanofi to amend a patent on its prostate cancer drug Jevtana, closing the door on a...To view the full article, register now.
Already a subscriber? Click here to view full article